1,167,382 Shares in Septerna, Inc. $SEPN Purchased by Primecap Management Co. CA

Primecap Management Co. CA bought a new stake in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,167,382 shares of the company’s stock, valued at approximately $39,096,000.

Several other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in Septerna during the 1st quarter worth about $906,000. TRV GP VI LLC bought a new position in shares of Septerna in the 2nd quarter valued at about $141,048,460,000. First Light Asset Management LLC grew its holdings in shares of Septerna by 18.0% in the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after acquiring an additional 112,049 shares in the last quarter. TRV GP V LLC acquired a new stake in shares of Septerna in the second quarter valued at about $208,160,143,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Septerna in the first quarter valued at about $21,334,000.

Insiders Place Their Bets

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $27,897.74. This trade represents a 73.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Daniel D. Long sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the completion of the transaction, the senior vice president directly owned 96,412 shares in the company, valued at $3,323,321.64. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 61,030 shares of company stock worth $2,329,666 over the last three months. Insiders own 5.80% of the company’s stock.

Septerna Price Performance

SEPN stock opened at $40.25 on Thursday. Septerna, Inc. has a one year low of $11.70 and a one year high of $51.10. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -74.54 and a beta of 2.29. The company has a fifty day moving average price of $37.15 and a two-hundred day moving average price of $30.65.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. The company had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. Research analysts anticipate that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SEPN has been the subject of several recent research reports. Wells Fargo & Company increased their price target on Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating and set a $49.00 price objective on shares of Septerna in a research note on Tuesday, August 11th. JonesTrading raised their target price on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Friday, July 17th. Finally, Truist Financial boosted their price objective on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Septerna presently has an average rating of “Moderate Buy” and a consensus price target of $52.44.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.